Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on Etanercept therapy with or without methotrexate

Annals of the Rheumatic Diseases

Volumn 67, Issue 10, 2008, Pages 1444-1447

  Kavanaugh, A ^a,f   Klareskog, L ^b   Van Der Heijde, D ^c   Li, J ^d   Freundlich, B ^e   Hooper, M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d AMGEN INC   (United States)

^e PFIZER INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; FEMALE; HUMAN; JOINT RADIOGRAPHY; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53149141023     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2008.094524     Document Type: Article

References (15)

1. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
2. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a doubleblind, randomized trial. Arthritis Rheum 2006;54:1063-74.
3. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. NEngl J Med 2000;343:1586-93.
4. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
5. Landewe R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate. Arthritis Rheum 2006;54:3119-25.
6. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy study. Arthritis Rheum 2005;52:1020-30.
7. Emery P, Reginster J-Y, Appelboom T, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology 2001;40:699-702.
8. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006;65(Suppl):iii2-15.
9. Konttinen YT, Seitsalo S, Lehto M, Santavirta S. Current management: management of rheumatic diseases in the ra of biological anti-rheumatic drugs. Acta Orthop 2005;76:614-19.
10. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63.
11. Mok C-C, Consensus statements on the indications and monitoring of anti-tumor necrosis factor (TNF) therapy for rheumatic diseases in Hong Kong. Hong Kong Bull Rheum Dis 2005;5:19-25.
12. Rodriguez-Valverde V, Caliz RC, Alvaro Alvaro-Gracia JM, et al. Ill Actualizacion del consenso de la Sociedad Espanola de Reumatologia sobre terapia biologica en la artritis reumatoide. Reumatol Clin 2006;2(Supl 2):S52-9.
13. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:2793-806.
14. Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
15. Lannone F, Trotta F, Monteccuco C, et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007;66:249-52.